Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Analysts

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) have received a consensus recommendation of "Hold" from the seven brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $3.2250.

A number of equities research analysts have recently commented on LXRX shares. Citigroup lifted their price objective on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the company a "buy" rating in a research report on Thursday, August 7th. Wall Street Zen raised Lexicon Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, October 4th. HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 8th.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Hudson Bay Capital Management LP purchased a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at $26,000. R Squared Ltd acquired a new position in Lexicon Pharmaceuticals in the second quarter valued at $28,000. Catalyst Funds Management Pty Ltd acquired a new position in Lexicon Pharmaceuticals in the second quarter valued at $51,000. Straight Path Wealth Management acquired a new position in Lexicon Pharmaceuticals in the first quarter valued at $29,000. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in Lexicon Pharmaceuticals by 77.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company's stock valued at $62,000 after acquiring an additional 28,594 shares during the last quarter. Hedge funds and other institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Stock Performance

Lexicon Pharmaceuticals stock opened at $1.42 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.16 and a current ratio of 4.16. The stock has a fifty day moving average of $1.24 and a two-hundred day moving average of $0.94. The company has a market capitalization of $516.03 million, a price-to-earnings ratio of -4.30 and a beta of 1.23. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.18.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $28.87 million during the quarter, compared to the consensus estimate of $4.87 million. Lexicon Pharmaceuticals had a negative return on equity of 83.63% and a negative net margin of 206.43%. On average, analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.